Literature DB >> 16636176

Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.

S Hinan Ahmed1, Leslie L Clark, Weems R Pennington, Carson S Webb, D Dirk Bonnema, Amy H Leonardi, Catherine D McClure, Francis G Spinale, Michael R Zile.   

Abstract

BACKGROUND: Chronic hypertension may cause left ventricular (LV) remodeling, alterations in cardiac function, and the development of chronic heart failure (CHF). Changes in the composition of the extracellular matrix (ECM) known to occur in hypertension are believed to be causally related to these structural, functional, and clinical outcomes. However, whether the determinants of ECM composition, such as the balance between ECM proteases (matrix metalloproteinases [MMPs]) and their tissue inhibitors [TIMPs]), are altered in hypertensive heart disease is unknown. METHODS AND
RESULTS: Plasma MMP-2, -9, and -13 values, TIMP-1 and -2 values, and Doppler echocardiography images were obtained for 103 subjects divided into 4 groups: (1) reference subjects (CTL) with no evidence of cardiovascular disease, (2) hypertensive (HTN) subjects with controlled blood pressure and no LV hypertrophy, (3) hypertensive subjects with controlled blood pressure and with LV hypertrophy (HTN+LVH) but no CHF, and (4) hypertensive subjects with controlled blood pressure, LVH, and CHF (HTN+LVH+CHF). Compared with CTL, patients with HTN had no significant changes in any MMP or TIMP. Patients with HTN+LVH had decreased MMP-2 and MMP-13 values and increased MMP-9 values. Only patients with HTN+LVH+CHF had increased TIMP-1 values. A TIMP-1 level >1200 ng/mL was predictive of CHF.
CONCLUSIONS: Patients with hypertension but normal LV structure and function had normal MMP/TIMP profiles. Changes in MMP profiles that favor decreased ECM degradation were associated with LVH and diastolic dysfunction. An increased TIMP-1 level predicted the presence of CHF. Although these findings should be confirmed in a larger prospective study, these data do suggest that changes in the MMP/TIMP balance may play an important role in the structural, functional, and clinical manifestations of hypertensive heart disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16636176     DOI: 10.1161/CIRCULATIONAHA.105.573865

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  124 in total

1.  Gene expression profiling of DEHP-treated cardiomyocytes reveals potential causes of phthalate arrhythmogenicity.

Authors:  Nikki Gillum Posnack; Norman H Lee; Ronald Brown; Narine Sarvazyan
Journal:  Toxicology       Date:  2010-10-08       Impact factor: 4.221

2.  Matrix metalloproteinase-9 and plasminogen activator inhibitor-1 are associated with right ventricular structure and function: the MESA-RV Study.

Authors:  Steven M Kawut; R Graham Barr; W Craig Johnson; Harjit Chahal; Harikrishna Tandri; Aditya Jain; Michael R Bristow; Jorge R Kizer; Emilia Bagiella; Joao A C Lima; David A Bluemke
Journal:  Biomarkers       Date:  2010-10-05       Impact factor: 2.658

3.  LV reverse remodeling imparted by aortic valve replacement for severe aortic stenosis; is it durable? A cardiovascular MRI study sponsored by the American Heart Association.

Authors:  Robert W W Biederman; James A Magovern; Saundra B Grant; Ronald B Williams; June A Yamrozik; Diane A Vido; Vikas K Rathi; Geetha Rayarao; Ketheswaram Caruppannan; Mark Doyle
Journal:  J Cardiothorac Surg       Date:  2011-04-14       Impact factor: 1.637

4.  Plasma profiling determinants of matrix homeostasis in paediatric dilated cardiomyopathy.

Authors:  Tain-Yen Hsia; Jeremy M Ringewald; Robert E Stroud; Nadia Roessler; Nidhi Kumar; Scott T Reeves; Francis G Spinale
Journal:  Cardiol Young       Date:  2010-10-27       Impact factor: 1.093

Review 5.  Matrix metalloproteases: underutilized targets for drug delivery.

Authors:  Deepali G Vartak; Richard A Gemeinhart
Journal:  J Drug Target       Date:  2007-01       Impact factor: 5.121

6.  Changes in Biomarker Profile and Left Ventricular Hypertrophy Regression: Results from the Frequent Hemodialysis Network Trials.

Authors:  Christopher T Chan; George A Kaysen; Gerald J Beck; Minwei Li; Joan Lo; Michael V Rocco; Alan S Kliger
Journal:  Am J Nephrol       Date:  2018-04-05       Impact factor: 3.754

7.  Inhibiting Fibronectin Attenuates Fibrosis and Improves Cardiac Function in a Model of Heart Failure.

Authors:  Iñigo Valiente-Alandi; Sarah J Potter; Ane M Salvador; Allison E Schafer; Tobias Schips; Francisco Carrillo-Salinas; Aaron M Gibson; Michelle L Nieman; Charles Perkins; Michelle A Sargent; Jiuzhou Huo; John N Lorenz; Tony DeFalco; Jeffery D Molkentin; Pilar Alcaide; Burns C Blaxall
Journal:  Circulation       Date:  2018-09-18       Impact factor: 29.690

Review 8.  Circulating biomarkers in patients with heart failure and preserved ejection fraction.

Authors:  Eileen O'Meara; Simon de Denus; Jean-Lucien Rouleau; Akshay Desai
Journal:  Curr Heart Fail Rep       Date:  2013-12

9.  Effect of metabolic syndrome risk factors and MMP-2 genetic variations on circulating MMP-2 levels in childhood obesity.

Authors:  Vanessa A Belo; Marcelo R Luizon; Patrícia C Carneiro; Valéria A Gomes; Riccardo Lacchini; Carla M M Lanna; Debora C Souza-Costa; Jose E Tanus-Santos
Journal:  Mol Biol Rep       Date:  2012-12-16       Impact factor: 2.316

10.  Dynamic changes in matrix metalloprotienase activity within the human myocardial interstitium during myocardial arrest and reperfusion.

Authors:  Francis G Spinale; Christine N Koval; Anne M Deschamps; Robert E Stroud; John S Ikonomidis
Journal:  Circulation       Date:  2008-09-30       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.